1. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Issue 10 (October 2015) Authors: Koh, Christopher; Canini, Laetitia; Dahari, Harel; Zhao, Xiongce; Uprichard, Susan L; Haynes-Williams, Vanessa; Winters, Mark A; Subramanya, Gitanjali; Cooper, Stewart L; Pinto, Peter; Wolff, Erin F; Bishop, Rachel; Ai Thanda Han, Ma; Cotler, Scott J; Kleiner, David E; Keskin, Onur; Idilman, Rama... Journal: Lancet infectious diseases Issue: Volume 15:Issue 10(2015:Oct.) Page Start: 1167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Issue 10 (October 2015) Authors: Koh, Christopher; Canini, Laetitia; Dahari, Harel; Zhao, Xiongce; Uprichard, Susan L; Haynes-Williams, Vanessa; Winters, Mark A; Subramanya, Gitanjali; Cooper, Stewart L; Pinto, Peter; Wolff, Erin F; Bishop, Rachel; Ai Thanda Han, Ma; Cotler, Scott J; Kleiner, David E; Keskin, Onur; Idilman, Rama... Journal: Lancet infectious diseases Issue: Volume 15:Issue 10(2015:Oct.) Page Start: 1167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗